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A B S T R A C T
The aim of this study was to obtain the relevant information on antibiotic use in a 750-bed Croatian university hospi-
tal. The study has been designed as a 2-point prevalence interventional analysis. For each patient on antibiotic therapy,
diagnosis, indication for treatment, antibiotic therapy, dosage and route of administration together with the results of
microbiological studies (if available) were obtained. After the first prevalence analysis in 2001, a restriction on unlimited
antibiotic use was introduced. The second analysis, performed in 2002, after restrictions on antibiotic use, revealed re-
ductions in the rates of restricted release antibiotics and overall antibiotic use with decreases from 38.6% to 36.9% and
23.4% to 23.2% respectively (p=0.87). The first survey showed that the 5 most often prescribed antibiotics in the therapy
of bacterial infections were: gentamicin, other aminoglycosides, carbapenems, amoxycillin+clavulanate and vancomy-
cin with proportions of 14.8%, 10.3%, 8.2%, 7% and 7% respectively. In the year 2002, the most prescribed antimicrobial
drugs in the therapy of bacterial infections were: gentamicin, quinolones, vancomycin, carbapenems and cefuroxime with
proportions of 18.6%, 11.4%, 9.7%, 9.3% and 8% respectively. A reduction in the proportions of doubtful antibiotic ther-
apy, from 24.6% before the intervention, to 24.2% after the restrictions, accompanied by a 0.4% rise in the rates of indi-
cated antibiotic therapy was also observed (p=0.93). Our study shows that restrictions on formerly unlimited use of
antimicrobials, even when leading to an improvement in their prescribing, do not necessarily cause rapid and significant
reduction in the overall use of antibiotics or explicit positive financial effects.
Key words: antibiotic, antimicrobial therapy, antimicrobials, treatment, optimization, reduction, hospital
Introduction
Control of the infectious diseases by vaccination, anti-
biotics and public health measures is surely one of the
greatest achievements of modern medicine. Under the
pressure of evolutionary adaptation however, many mi-
croorganisms became resistant to antibiotics to which
they have been formerly susceptible. Rising microbial re-
sistance in turn spawned the development of many new,
expensive, broad spectrum antibiotics that were widely
available, readily accepted and usually overzealously or
indiscriminately used by the physicians, contributing in
that way further to the rising rates of antimicrobial re-
sistance and increase in health care costs. In response,
many experts and organizations have called for increased
efforts to limit the overuse of antimicrobial agents both
in community and hospital settings1–4.
The aim of this study was to obtain the relevant infor-
mation on antimicrobial use in the largest university af-
filiated hospital in Croatia. Among other things, special
attention was given to: overall use of antibiotics per de-
partment, indications for use, source of infections and
utilization of microbiological studies. We used a point-
prevalence interventional method.
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Materials and Methods
Setting
University Hospital Rebro is a 750-bed tertiary care
facility in Zagreb, Croatia. The hospital has undergradu-
ate and postgraduate teaching courses including training
programmes for residents in internal medicine, pediat-
rics, neurology, psychiatry, ophthalmology, urology, on-
cology, several surgery subspecialties, neurosurgery, nu-
clear medicine and clinical pharmacology.
Unit of Clinical Pharmacology provides supervision
and dose monitoring for patients on restricted release
antimicrobial agents. Clinical pharmacology counseling
on appropriate dosing, possible interactions and allergic
reactions is available to all hospital wards. Bulletins con-
taining information on drugs, antimicrobial dosing and
cost, recommendations for empiric therapy and micro-
bial resistance patterns in the hospital are distributed
monthly to all physicians.
Study design
This study had been designed as a 2-point prevalence
interventional analysis (interrupted time series design –
ITS). All hospitalized patients have been surveyed for an-
tibiotic treatment, once a year for two consecutive years.
For each patient on antibiotic therapy, diagnosis, indica-
tion for treatment or prophylaxis, antibiotic treatment,
dosage and route of administration together with the re-
sults of microbiological studies (if available) were ob-
tained. Members of the unit of Clinical Pharmacology
performed data collection and registration.
After the first point prevalence analysis in 2001, a re-
striction on unlimited antibiotic prescribing was intro-
duced, consisting of mandatory written forms that were
required by the central pharmacy for every parenterally
prescribed antibiotic and an obligatory written request
for every restricted release antibiotic, authorized only af-
ter consultation with clinical pharmacologist, microbiol-
ogist or an ICU attending physician. Within 48 hours of
the start of therapy, it was determined whether antibi-
otic therapy was necessary. A point system for indicated
antibiotic therapy was introduced in order to serve as
guidelines to physicians for the improvement of antibi-
otic prescribing (Table 1). The second point prevalence
analysis was performed in 2002.
The annual antibiotic costs were calculated in US dol-
lars for both periods, based on the prices of antimicrobial
agents provided by the hospital pharmacy.
Data analysis
Statistical analysis was performed using STATISTI-
CA version 6.1 software. Where appropriate, data were
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TABLE 1
POINT SYSTEM FOR INDICATED ANTIBIOTIC THERAPY
Sign / Laboratory value Points
Positive blood culture 3
Positive microbiological studies 2
Body temperature > 37.5 °C 1
L >10x109 1
L >10x109 + neseg. L 2
CRP >10 1
Clinical signs of infection 1
Other laboratory or RTG signs of infection 1
Points <3 doubtful indication for antibiotic therapy,
3 or >3 necessary antibiotic therapy
TABLE 2
ANTIBIOTICS USAGE COMPARISON – UNIVERSITY HOSPITAL REBRO
Department
2001. 2002.
No. Beds
Patients on
antibiotics
% No. Beds
Patients on
antibiotics
%
Physiatric 14 0 0.0 14 0 0.0
Internal medicine 145 55 37.9 138 48 34.78
Cardiosurgery 25 7 28.0 22 11 50.0
Surgery 116 35 30.2 117 40 34.19
Cardiology 59 6 10.2 60 5 8.33
Neurosurgery 42 7 16.7 49 12 24.49
Neurology 115 16 13.9 114 12 10.53
Nuclear medicine 12 0 0.0 11 0 0.0
Ophthalmology 76 27 35.5 68 22 32.35
Oncology 78 13 16.6 64 8 12.5
Pediatrics 110 33 30.0 112 35 31.25
Psychiatry 84 0 0.0 78 1 1.28
Urology 52 17 32.7 44 13 29.55
University Hospital Rebro 928 216 23.4 891 207 23.2
analyzed using chi-square tests. The Wilcoxon signed
rank test was used to compare pre- and post-interven-
tional points awarded for indicated antibiotic therapy.
The costs of antimicrobial therapies were based on con-
current wholesale drug prices in Croatia. The hospital’s
review board approved the protocol of this study.
Results
The point prevalences of antibiotic use for the whole
hospital in 2001 and 2002 were 23.4% and 23.2% respec-
tively. In the 2001, the highest prevalences of antibiotic
treatment were observed in the Departments of Internal
medicine, Ophthalmology, Urology, Surgery and Pediat-
rics with 37.9%, 35.5%, 32.7%, 30.2% and 30% respec-
tively. A year later, highest rates of antibiotic therapy
were noted in the Departments of Cardio-surgery, Inter-
nal medicine, Surgery, Ophthalmology and Pediatrics
with 50%, 34.78%, 34.19%, 32.35% and 31.25% respec-
tively (Table 2).
The first survey showed that the 5 most often pre-
scribed antibiotics in the therapy of bacterial infections
were: gentamicin, other aminoglycosides, carbapenems,
amoxycillin+clavulanate and vancomycin with propor-
tions of 14.8%, 10.3%, 8.2%, 7% and 7% respectively. The
following year, the most prescribed antimicrobial drugs
were: gentamicin, quinolones, vancomycin, carbapenems
and cefuroxime with proportions of 18.6%, 11.4%, 9.7%,
9.3% and 8% respectively (Table 3).
Out of all prescribed antimicrobial drugs in the first
analysis, 61.4% were first line, while 38.6% were re-
stricted release antibiotics. The second survey showed a
decrease in the rates of restricted release antibiotics to
36.9% (p=0.87), see Table 4.
It is worth noting that we observed a reduction in the
proportions of doubtful antibiotic therapy, from 24.6%
before the intervention, to 24.2% after the introduction
of prescription restrictions, accompanied by a 0.4% rise
in the rates of indicated antibiotic therapy (p=0.93).
Moreover, overall reduction of antibiotic costs between
the compared periods amounted to 445 251 $ in savings.
The commonest conditions requiring antibiotic treat-
ment in the first study were: urinary tract infections, sep-
sis, pneumonia, fever and respiratory tract infections with
prevalence of 24.3%, 10.7%, 10%, 9.3% and 6.4% respec-
tively. The following year, diagnoses that most often lead to
antibiotic use were: urinary tract infections, fever, pneumo-
nia, sepsis and other conditions with prevalence of 26.8%,
12.8%, 11.4%, 8.7% and 11% respectively (Table 5).
In addition, all departments of the hospital, with the
exception of Urology and Surgery, showed a significant
increase in the mean number of points allocated for indi-
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TABLE 3
PROPORTIONS OF THE 10 MOST OFTEN PRESCRIBED ANTIBIOTICS FOR THE THERAPY OF BACTERIAL INFECTIONS
2001 2002
Antibiotic N No PDD % Antibiotic N No PDD %
Gentamicin 1 36 14.8 Gentamicin 1 44 18.6
Aminoglycosides (amikacin, netilmicin) 2 25 10.3 Quinolones 2 27 11.4
Carbapenems (imipenem, meropenem) 3 20 8.2 Vancomycin 3 23 9.7
Amoxycillin+clavulanate 4 17 7.0
Carbapenems (imipenem,
meropenem)
4 22 9.3
Vancomycin 5 17 7.0 Cefuroxime 5 19 8.0
III generation cephalosporins
(ceftazidime, ceftriakson)
6 16 6.6 Metronidazole 6 19 8.0
Cefuroxime 7 16 6.6
III generation cephalosporins
(ceftazidime, ceftriakson)
7 15 6.3
Cloxacillin 8 15 6.2 Amoxycillin+clavulanate 8 11 4.6
Quinolones 9 14 5.8 Cloxacillin 9 11 4.6
Metronidazole 10 13 5.3 Cefepime 10 10 4.2
No PDD – number of prescribed daily doses
TABLE 4
PROPORTION OF RESTRICTED RELEASE ANTIBIOTICS AND
DOUBTFUL ANTIBIOTIC USE IN THE THERAPY OF BACTERIAL
INFECTIONS
Antibiotic
2001 2002
N % N %
First line 87 61.4 94 63.1
Restricted release 53 38.6 55 36.9
Total 140 100 149 100
Indicated 104 75.4 113 75.8
Doubtful 34 24.6 36 24.2
Total 138* 100 149 100
* Two formularies were excluded from analysis due to the fact
that they were inappropriately filled in
cated antibiotic therapy (Table 6), according to the point
system for antibiotic therapy that had been introduced
together with the limitations on antibiotic use (Table 1).
Discussion
The goal of our antibiotic policy is to ensure the cor-
rect and rational use of antimicrobial drugs. Having ex-
perienced rising drug costs, coupled with increasing mi-
crobial drug resistance, fund limits imposed by a national
health system undergoing a reform and struggling econ-
omy of a postwar, transitional country, hospital’s team
for drug monitoring decided to assess the present antibi-
otic policy by conducting a point prevalence study.
It showed a prevalence of antibiotic use of 23.4%,
which is in comparison with the results of other preva-
lence studies (25% to 60%) somewhat lower5–9. However,
it highlighted a high prevalence of restricted release anti-
biotics (38.6%), with carbapenems and vancomycin being
among the top five most prescribed antimicrobial drugs.
The second analysis, performed after the introduction
of restrictions on antibiotic use, divulged reductions in
the rates of restricted release antibiotics and overall anti-
biotic use with decreases from 38.6% to 36.9% and 23.4%
to 23.2% respectively. It also demonstrated an improve-
ment in antibiotic prescribing throughout the hospital.
Even though statistically insignificant, the decrease in
antibiotic use could have, at least partially, accounted for
the saving of 445 251 $, representing a 15% of the annual
hospital budget for antimicrobial agents. Although we
are unaware of any other concurrent changes in practice
that could have preferentially affected antibiotic use dur-
ing our research, confounding variables such as: random
fluctuations, seasonal effects or secular trends (e.g. de-
crease in price of antimicrobials during the intervention)
cannot be excluded.
The scoring method for indicated antibiotic use (Ta-
ble 1) has been devised in collaboration with the col-
leagues at the University Hospital Rijeka (Croatia) and
the Karolinska Institutet (Sweden)10. It has generally
been well accepted by the clinicians of our hospital, al-
though the highest acceptance rates could be observed
among the residents. The mandatory written formular-
ies required by the central pharmacy for parenteral and
restricted release antibiotics contain this scoring system,
thus serving as a helpful tool for residents in coping with
the differences in antimicrobial prescribing patterns be-
tween various departments.
The randomized controlled trial (RCT) is seen as the
criterion standard methodology for the evaluation of
health care interventions11. However, there are many in-
stances where it is impossible or impractical to use RCTs.
In an interrupted time series (ITS) design, data are col-
lected over time before and after an intervention is intro-
duced to detect whether the intervention has an effect
significantly greater than the underlying secular trend.
The greatest threat to validity of an ITS study is that an
event other than the control of the researchers occurred
at the same time as the intervention, thereby making ca-
sual inferences impossible12. A recent analysis has dem-
onstrated that this threat could not be ruled out explic-
itly in 66% of the performed ITS studies13.
Further studies are required to clarify why physicians
overzealously prescribe antibiotics to hospitalized pa-
tients14. Patients’ demands for antimicrobials are often
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TABLE 5
COMPARISON OF THE COMMONEST CONDITIONS REQUIRING ANTIBIOTIC TREATMENT
Diagnosis
2001
Diagnosis
2002
N No % N No %
UTI 1 34 24.3 UTI 1 40 26.8
Sepsis 2 15 10.7 Fever 2 19 12.8
Pneumonia 3 14 10.0 Pneumonia 3 17 11.4
Fever 4 13 9.3 Sepsis 4 13 8.7
RTI 5 9 6.4 Other 5 11 7.4
UTI – urinary tract infection, RTI – respiratory tract infection
TABLE 6
DEPARTMENTS WITH CORRESPONDING MEAN POINT
NUMBERS FOR INDICATED ANTIBIOTIC THERAPY
Department
2001 2002
Number of
mean points
Number of
mean points
Pediatrics* 4.2 5.8
Urology 4.0 3.6
Internal medicine* 3.7 5.0
Neurosurgery* 3.7 6.0
Oncology* 3.6 4.9
Cardiosurgery* 3.3 5.8
Neurology* 3.3 4.8
Cardiology* 3.0 6.0
Surgery 3.0 3.2
Ophthalmology† – 0.8
Physiatric department† – 2.0
University Hospital Rebro* 3.53 5.01
* Wilcoxon signed rank test p<0.05, † departments that have
not supplied data for 2001 were excluded from analysis
cited as a reason for unnecessary prescriptions in the
outpatient setting15. Possible reasons proposed for exces-
sive antibiotic use in hospitals include acutely ill and
complex status of patients, diagnostic uncertainty, pres-
sure to keep lengths of stay short, and prescribing by
clinically inexperienced physicians as in teaching hospi-
tals16. Physicians may also have a low threshold to give
antimicrobials, because they believe that these agents
are unlikely to cause harm, and in the same time ignore
the possible consequences not only for the individual pa-
tient but also for the broader microbiological environ-
ment14.
There are few publications assessing the effect of
guidelines on antibiotic utilization. The best method(s)
to improve use is still not known17. Multidisciplinary ap-
proach, continuity of the process and the roles of clinical
pharmacologists, microbiologists and infectious disease
specialists are usually stressed4–6,18–25.
Our study shows that restrictions on formerly unlim-
ited use of antimicrobials, even when leading to an im-
provement in their prescribing, do not necessarily cause
rapid and significant reduction in the overall use of anti-
biotics or explicit positive financial effects.
Take home messages:
• Rising rates of antimicrobial resistance and increase in
health care costs are the primary reasons for increased
efforts to limit the overuse of antimicrobial agents
both in community and hospital settings.
• Possible reasons for excessive antibiotic use in hospi-
tals include acutely ill and complex status of patients,
diagnostic uncertainty, pressure to keep lengths of stay
short, and prescribing by clinically inexperienced phy-
sicians as in teaching hospitals.
• The best method(s) to improve antibiotic use is still
not known.
• Many authorities emphasize multidisciplinary approach,
continuity of the process of antimicrobial use control
and the roles of clinical pharmacologists, microbiolo-
gists and infectious disease specialists.
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PROGRAM OPTIMIZACIJE UPOTREBE ANTIMIKROBNIH LIJEKOVA U NAJVE]OJ HRVATSKOJ
SVEU^ILI[NOJ BOLNICI: KORISTI OD RESTRIKCIJA NA NEOGRANI^ENU UPOTREBU
ANTIMIKROBNIH LIJEKOVA
S A @ E T A K
Svrha ovog istra`ivanja bila je sakupiti relevantne informacije o upotrebi antimikrobnih lijekova u hrvatskoj sveu-
~ili{noj bolnici sa 750 kreveta. Istra`ivanje je dizajnirano kao intervencijska analiza s 2 to~ke prevalencije. Za svakog
bolesnika na antimikrobnoj terapiji sakupljeni su podaci o antimikrobnoj terapiji, dijagnozi, indikaciji za terapiju, dozi i
putu primjene lijeka zajedno s rezultatima mikrobiolo{ke obrade (ukoliko su bili dostupni). Nakon analize prve to~ke
prevalencije u 2001 godini, uvedena je restrikcija na neograni~eno propisivanje antimikrobnih lijekova. Druga analiza,
provedena 2002, nakon uvedenog ograni~enja na antimikrobne lijekove, pokazuje smanjenje postotka upotrebe anti-
mikrobnih lijekova s ograni~enim propisivanjem s 38.6% na 36.9% te smanjenje upotrebe svih antimikrobnih lijekova s
23.4% na 23.2% (p=0.87). U prvom istra`ivanju pet najpropisivanijih antimikrobnih lijekova u terapiji bakterijskih
infekcija su bili: gentamicin (14.8%), drugi aminoglikozidi (10.3%), karbapenemi (8.2%), amoksicilin s klavulanskom
kiselinom (7%) i vankomicin (7%). U 2002 godini, najpropisivaniji lijekovi u terapiji bakterijskih infekcija bili su: genta-
micin (18.6%), kinoloni (11.4%), vankomicin (9.7%), karbapenemi (9.3%) i cefuroksim (8%). Tako|er je zabilje`eno
smanjenje postotka upitne antimikrobne terapije, s 24.6% prije intervencije, na 24.2% nakon restrikcija, uz 0.4% porast
udjela indicirane antimikrobne terapije (p=0.93). Na{e istra`ivanje pokazuje da restrikcije na prethodno neograni~enu
upotrebu antimikrobnih lijekova, ~ak i kada dovode do pobolj{anja u njihovu propisivanju, ne uzrokuju nu`no brzo i
zna~ajno smanjenje ukupne potro{nje antimikrobnih lijekova ili jasno pozitivne financijske u~inke.
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